Arnold M, Morgan E, Rumgay H et al (2022) Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast (Edinburgh, Scotland) 66:15–23

Article  PubMed  Google Scholar 

AlFakeeh A, Brezden-Masley C (2018) Overcoming endocrine resistance in hormone receptor-positive breast cancer. Curr Oncol 25(Suppl 1):S18–S27

Article  CAS  PubMed  PubMed Central  Google Scholar 

Burstein HJ (2020) Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer. N Engl J Med 383(26):2557–2570

Article  CAS  PubMed  Google Scholar 

Asghar U, Witkiewicz AK, Turner NC et al (2015) The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discovery 14(2):130–146

Article  CAS  PubMed  Google Scholar 

Campbell RA, Bhat-Nakshatri P, Patel NM et al (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276(13):9817–9824

Article  CAS  PubMed  Google Scholar 

Presti D, Quaquarini E (2019) The PI3K/AKT/mTOR and CDK4/6 pathways in endocrine resistant HR+/HER2- metastatic breast cancer: biological mechanisms and new treatments. Cancers (Basel) 11(9):1242

Article  CAS  PubMed  Google Scholar 

Wang L, Da H, Li X et al (2020) Comparison of CD4/6 inhibitors, PI3K inhibitors, and mTOR inhibitors for patients with advanced HR+/HER2-breast cancer: a network meta-analysis of 19 RCTs. Breast J 26(9):1862–1866

Article  CAS  PubMed  Google Scholar 

Leung JH, Leung HWC, Wang SY et al (2021) Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis. Expert Opin Drug Saf 20(8):949–957

Article  CAS  PubMed  Google Scholar 

Xu H, Wang Y, Han Y et al (2022) CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2- negative metastatic breast cancer: an updated systematic review and network meta-analysis of 28 randomized controlled trials. Front Oncol 12:956464

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marshall SF, Burghaus R, Cosson V et al (2016) Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT Pharmacometrics Syst Pharmacol 5(3):93–122

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mould DR (2012) Model-based meta-analysis: an important tool for making quantitative decisions during drug development. Clin Pharmacol Ther 92(3):283–286

Article  CAS  PubMed  Google Scholar 

Li T, Yu J, Hou M et al (2023) Quantitative evaluation of therapy options for relapsed/refractory diffuse large B-cell lymphoma: a model-based meta-analysis. Pharmacol Res 187:106592

Article  CAS  PubMed  Google Scholar 

Wu L, Chen J, Cai R et al (2023) Difference in efficacy and safety of anti-CD19 chimeric antigen receptor T-cell therapy containing 4–1BB and CD28 co-stimulatory domains for B-cell acute lymphoblastic leukemia. Cancers (Basel) 15(10):2767

Article  CAS  PubMed  Google Scholar 

Gong Y, Sui Z, Lv Y et al (2023) LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data. Eur J Clin Pharmacol 79(10):1321–1332

Article  CAS  PubMed  Google Scholar 

Seidman AD, Maues J, Tomlin T et al (2020) The evolution of clinical trials in metastatic breast cancer: design features and endpoints that matter. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting 40:1–11

PubMed  Google Scholar 

Tankova T, Senkus E, Beloyartseva M et al (2022) Management strategies for hyperglycemia associated with the α-selective PI3K inhibitor alpelisib for the treatment of breast cancer. Cancers (Basel) 14(7):1598

Article  CAS  PubMed  Google Scholar 

Nunnery SE, Mayer IA (2019) Management of toxicity to isoform α-specific PI3K inhibitors. Ann Oncol 30(Suppl_10):x21–x6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harb WA (2015) Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options. Cancer Manag Res 7:37–46

Article  PubMed  PubMed Central  Google Scholar 

Robertson JFR, Di Leo A, Johnston S et al (2021) Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies. NPJ Breast Cancer 7(1):11

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rosa Mendoza ES, Moreno E, Caguioa PB (2013) Predictors of early distant metastasis in women with breast cancer. J Cancer Res Clin Oncol 139(4):645–652

Article  PubMed  Google Scholar 

Spring LM, Wander SA, Andre F et al (2020) Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet (London, England) 395(10226):817–827

Article  CAS  PubMed  Google Scholar 

Llombart-Cussac A, Pérez-García JM, Bellet M et al (2021) Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer: a randomized clinical trial. JAMA Oncol 7(12):1791–1799

Article  PubMed  Google Scholar 

Slamon DJ, Neven P, Chia S et al (2018) Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36(24):2465–2472

Article  CAS  PubMed  Google Scholar 

Slamon DJ, Neven P, Chia S et al (2020) Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 382(6):514–524

Article  CAS  PubMed  Google Scholar 

Slamon DJ, Neven P, Chia S et al (2021) Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Annals of oncology : Official Journal of the European Society for Medical Oncology 32(8):1015–1024

Article  CAS  PubMed  Google Scholar 

Fribbens C, O’Leary B, Kilburn L et al (2016) Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 34(25):2961–2968

Article  CAS  PubMed  Google Scholar 

Brett JO, Spring LM, Bardia A et al (2021) ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res 23(1):85

Article  CAS  PubMed  PubMed Central  Google Scholar 

Saad ED, Katz A, Hoff PM et al (2010) Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature. Ann Oncol 21(1):7–12

Article  CAS  PubMed  Google Scholar 

Ritchie G, Gasper H, Man J et al (2018) Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis. JAMA Oncol 4(4):522–528

Article  PubMed  PubMed Central  Google Scholar